We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

35 hedge funds and large institutions have $4.73M invested in Oramed Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more capital invested

Capital invested by funds: $1.97M → $4.73M (+$2.76M)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

74% more call options, than puts

Call options by funds: $584K | Put options by funds: $335K

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

13% more funds holding

Funds holding: 31 → 35 (+4)

3.03% more ownership

Funds ownership: 2.77% → 5.8% (+3%)

Holders
35
Holders Change
+4
Holders Change %
+12.9%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
5
Closed
5
Calls
$584K
Puts
$335K
Net Calls
+$249K
Net Calls Change
+$216K

Top Buyers

Rank Fund Capital Flow
1
JSMC
Jess S. Morgan & Co
California
+$1.28M
2
PF
Phoenix Financial
Israel
+$612K
3
EMG
ETF Managers Group
New Jersey
+$305K
4
Renaissance Technologies
Renaissance Technologies
New York
+$120K
5
LP
LMR Partners
United Kingdom
+$111K

Top Sellers

Rank Fund Capital Flow
1
IAM
ICM Asset Management
Washington
-$119K
2
Marshall Wace
Marshall Wace
United Kingdom
-$97.7K
3
Millennium Management
Millennium Management
New York
-$40K
4
BFM
Boothbay Fund Management
New York
-$20.5K
5
Victory Capital Management
Victory Capital Management
Texas
-$20K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIAP
26
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$11K – – –
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$5K – – –
SPIA
28
Steward Partners Investment Advisory
New York
$4K – – –
SFS
29
Sowell Financial Services
Arkansas
$4K +$208 +62 +6%
Bank of America
30
Bank of America
North Carolina
$2K -$144 -43 -6%
JWA
31
JFS Wealth Advisors
Pennsylvania
$2K – – –
RWB
32
RMR Wealth Builders
New Jersey
$2K +$1.51K +450 New
IAM
33
ICM Asset Management
Washington
– -$119K -39,000 Closed
Millennium Management
34
Millennium Management
New York
– -$40K -13,091 Closed
Victory Capital Management
35
Victory Capital Management
Texas
– -$20K -6,274 Closed
JP Morgan Chase
36
JP Morgan Chase
New York
– -$10K -2,987 -100%
Osaic Holdings
37
Osaic Holdings
Arizona
– -$3K -1,000 Closed
Federated Hermes
38
Federated Hermes
Pennsylvania
– -$2K -536 Closed
OSAM
39
O'Shaughnessy Asset Management
Connecticut
– +$138 +41 New
TF
40
TimeScale Financial
Massachusetts
– +$282 +84 New
1
2

ORMP Hedge Fund Activity: Q2 2020 in Review

35 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2020, worth a combined $4.73M — up 141% from $1.97M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ORMP positions and 5 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.

The largest buyer was Jess S. Morgan & Co, adding an estimated $1.28M. The largest seller was ICM Asset Management, exiting entirely with an estimated $119K sold.

  • 35 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2020, up from 31 in Q1 2020.
  • Funds reported $4.73M of Oramed Pharmaceuticals stock for Q2 2020, up 141% quarter-over-quarter.
  • 9 funds opened new Oramed Pharmaceuticals positions in Q2 2020 and 5 closed out, a net change of +4 holders.
  • The largest Oramed Pharmaceuticals buyer in Q2 2020 was Jess S. Morgan & Co, an estimated $1.28M added.
  • The largest Oramed Pharmaceuticals seller in Q2 2020 was ICM Asset Management, an estimated $119K sold.

Based on aggregated 13F filings for Q2 2020.